Patient Name : Mr.
CHARAN Collected : 28/Jan/2025 12:00PM
Age/Gender : 36 Y 0 M 0 D /M Received : 28/Jan/2025 04:03PM
UHID/MR No : DVDI.0000006147 Reported : 28/Jan/2025 05:37PM
Visit ID : DVDIOPV14778 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC VIDYUTHNAGAR
IP/OP NO : Center location : Vidyuthnagar,Hyderabad
DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
C-REACTIVE PROTEIN CRP 9.3 mg/L <5 Latex Particle
(QUANTITATIVE) , SERUM Immunoturbidimetric
Comment:
C-reactive protein (CRP) is one of the most sensitive acute-phase reactants for inflammation. Measuring changes in the
concentration of CRP provides useful diagnostic information about the level of acuity and severity of a disease. Unlike ESR, CRP
levels are not influenced by hematologic conditions such as anemia, polycythemia etc.
Increased levels are consistent with an acute inflammatory process. After onset of an acute phase response, the serum CRP
concentration rises rapidly (within 6-12 hours and peaks at 24-48 hours) and extensively.Concentrations above 100 mg/L are
associated with severe stimuli such as major trauma and severe infection (sepsis).
Page 1 of 3
SIN No:BI23920576
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad
Patient Name : Mr.CHARAN Collected : 28/Jan/2025 12:00PM
Age/Gender : 36 Y 0 M 0 D /M Received : 28/Jan/2025 04:08PM
UHID/MR No : DVDI.0000006147 Reported : 28/Jan/2025 06:22PM
Visit ID : DVDIOPV14778 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC VIDYUTHNAGAR
IP/OP NO : Center location : Vidyuthnagar,Hyderabad
DEPARTMENT OF SEROLOGY
Test Name Result Unit Bio. Ref. Interval Method
HBsAg , SERUM 0.1 S/C UNITS ECLIA
Comment:
RESULTS IN S/Co UNITS Conclusion from Testing Algorithm
< 0.90 NON-REACTIVE
0.90 - < 1.00 INDETERMINATE
≥1.00 REACTIVE
Interpretation:
• This is a screening assay which detects the first serological marker of Hepatitis B as early as 4-16 weeks after exposure.
• It persists during acute illness and usually disappears 12-20 weeks after onset of symptoms. Persistence of HBsAg for more than
6 months indicates development of carrier state or chronic liver disease
• A negative test result does not exclude with certainty a possible exposure to or an infection with the hepatitis B virus.
• It is recommended that a positive result of HBsAg must be be confirmed using a different enzyme immunoassay kit or by using a
confirmatory assay based on neutralisation with human anti hepatitis B surface antibody and/or HBV PCR
• Based upon clinical history it may become necessary to test for presence of other markers of hepatitis B virus infection.
Page 2 of 3
SIN No:SE02544280
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad
Patient Name : Mr.CHARAN Collected : 28/Jan/2025 12:00PM
Age/Gender : 36 Y 0 M 0 D /M Received : 28/Jan/2025 04:08PM
UHID/MR No : DVDI.0000006147 Reported : 28/Jan/2025 08:00PM
Visit ID : DVDIOPV14778 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC VIDYUTHNAGAR
IP/OP NO : Center location : Vidyuthnagar,Hyderabad
DEPARTMENT OF SEROLOGY
Test Name Result Unit Bio. Ref. Interval Method
HEPATITIS A ANTIBODY (ANTI-HAV) 0.06 INDEX <0.4 ELFA
IgM , SERUM
Comment:
HEPATITIS A ANTIBODY (ANTI-HAV)
INTERPRETATION
(Index)
<0.4 NEGATIVE
0.4 - 0.5 EQUIVOCAL
≥ 0.5 POSITIVE
The diagnosis of a recent hepatitis A viral infection is usually indicated by a positive anti-HAV IgM serology. IgM can be detected
as soon as the first symptoms appear, and generally persist for 2 to 4 months.
In cases of active prevention, anti-HAV IgM can be detected in patient sera within two weeks following the first injection of the
vaccine. Detection of anti-HAV IgM aids in the diagnosis of acute hepatitis, but is not sufficient to validate post-vaccine immunity.
*** End Of Report ***
Page 3 of 3
SIN No:SE02544280
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad
PATIENT NAME : CHARAN REF. DOCTOR : SELF
ACCESSION NO : 0042YA005715 AGE/SEX : 36 Years Male
PATIENT ID : CHARM908654390 DRAWN : 28/01/2025 15:54:11
CLIENT PATIENT ID: OU00111462 RECEIVED : 28/01/2025 18:16:27
REPORTED : 31/01/2025 17:41:48
Test Report Status Final Results Units
MOLECULAR BIOLOGY
HAV RNA PCR
HAV RNA PCR NOT DETECTED
Interpretation(s)
HAV RNA PCR-Clinical Utility:
1. HAV RNA is detected in serum or plasma during the incubation period before onset of clinical symptoms, but disappears soon after onset of clinical illness. Peak HAV titer
occurs during the 2 weeks before and 1-week after onset of illness.
2. Immunoglobulin M (IgM) antibodies to HAV (anti-HAV IgM) are typically present at onset of symptoms, and remain detectable for an average of 3 to 6 months after
infection. HAV IgM may be negative in early infection (if collected within 5 to 7 days after onset of symptoms). Total antibodies to HAV are of extremely limited value in the
diagnosis of acute infection.
3. HAV RT-PCR is a rapid and sensitive test for detection of Hepatitis A Virus in the clinical specimens even before the onset of clinical symptoms.
Interpretation:
Detection of specific amplification band of 192 bp indicates presence of HAV virus RNA in the given sample. Absence of 192 bp amplimer indicates absence of HAV RNA in
the given sample. All the results should always be correlated with clinical status and history of the patient.
Limitations:
PCR is a highly sensitive technique common reasons for paradoxical results are contamination during specimen collection, selection of inappropriate specimens and inherent
PCR inhibitors in the specimen. Negative result could occur in case of very low viral load or due to clearance of HAV.
Test technique: Reverse Transcriptase - Polymerase Chain Reaction
References:
1. Journal of Clinical Microbiology, Nov1998, p. 3615-3617.
2. Journal of Clinical Microbiology, Sep''2004 p. 4329-4331.
**End Of Report**
*This test is performed at our Referral laboratory. Please refer to conditions of reporting.
This report is not valid for medico legal purposes.
TERMS AND CONDITIONS GOVERNING THIS REPORT
1. Reported results are for information and interpretation of the referring doctor or such other medical professionals,
who understandreporting units, reference ranges and limitation of technologies.Laboratories not be responsible for any
interpretation whatsoever.
2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the
verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same
parameter for the same patient (within subject biological variation).
4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be
communicated to the assigned regulatory bodies.
5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of
the laboratory.
6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.
